Bioorthogonal Drug Delivery via Selective Payload Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing biomaterials for drug delivery cannot be modulated after implantation and often exhibit an initial burst of activity, limiting their application in medical conditions requiring specific dosing regimens or when the most effective therapeutic agent is identified after implantation.
Innovation Solution
The use of bioorthogonal compositions comprising a support with attached bioorthogonal functional groups, which can selectively bind with complementary functional groups on functionalized payloads, allowing for targeted and controlled release of therapeutic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If existing biomaterials are used for drug delivery, then the initial burst of activity is achieved, but the ability to modulate or modify after implantation is lost
Solution Approach 1:
The system divides the drug delivery function into two separate components: a support composition implanted in the body and functionalized payloads administered systemically. This segmentation allows the support to provide structural stability while the payloads deliver the therapeutic agents, enabling both initial activity and post-implantation modulation through selective binding
Solution Approach 2:
Bioorthogonal functional groups serve as intermediaries between the support composition and functionalized payloads. These groups enable selective binding without interfering with biological systems, allowing the support to remain inert while facilitating controlled interaction with administered payloads for modifiable drug delivery
2Quantity of substance
If systemic medications are used for treatment, then broad coverage is achieved, but noxious side effects occur
Solution Approach 1:
The support composition is implanted at a specific target site in the body, creating a localized drug reservoir. When functionalized payloads are administered systemically, they bind selectively to the support at the target location, concentrating the therapeutic agent locally while minimizing systemic exposure and reducing side effects
Solution Approach 2:
The system utilizes the body's own circulation and natural distribution mechanisms to deliver functionalized payloads to the implanted support. The payloads self-administer to the target site through selective binding, eliminating the need for invasive local administration while maintaining targeted delivery
3Device complexity
If biomaterials are used as depots for therapeutic agents, then simplified delivery is achieved, but controlled release at different time points is limited
Solution Approach 1:
The system transforms a static implant into a dynamic, programmable drug delivery system. The support composition provides simplified structural stability, while the timing and amount of drug release are dynamically controlled by the administration schedule of functionalized payloads, enabling precise temporal control without increasing physical device complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables precise delivery of therapeutic agents to specific locations in the body, reducing side effects and improving treatment efficacy by allowing for controlled release and modulation of drug delivery over time.
Implementation Method 1
Bioorthogonal conjugation or click reactions are selective and orthogonal (non-interacting with) functionalities found in biological systems
Implementation Method 2
Bioorthogonal conjugation or click reactions are selective and orthogonal (non-interacting with) functionalities found in biological systems
Implementation Method 3
Existing biomaterials can serve as depots for therapeutic agents, which can be released to the body through diffusion or degradation
Data Source
AI summary
The present disclosure provides bioorthogonal compositions for delivering agents in a subject. The disclosure also provides methods of producing the compositions, as well as methods of using the same.